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ABSTRACT
Background. Uromodulin (Tamm–Horsfall protein) is the
most abundant protein excreted in the urine under physiological
conditions. It is exclusively produced in the kidney and secreted
into the urine via proteolytic cleavage. The involvement of
UMOD, the gene that encodes uromodulin, in rare autosomal
dominant diseases, and its robust genome-wide association with
the risk of chronic kidney disease suggest that the level of uro-
modulin in urine could represent a critical biomarker for kidney
function. The structure of uromodulin is complex, with multiple
disulﬁde bonds and typical domains of extracellular proteins.
Methods. Thus far, the conditions inﬂuencing stability and
measurement of uromodulin in human urine have not been
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systematically investigated, giving inconsistent results. In this
study, we used a robust, in-house ELISA to characterize the
conditions of sampling and storage necessary to provide a
faithful dosage of uromodulin in the urine.
Results. The levels of uromodulin in human urine were sig-
niﬁcantly affected by centrifugation and vortexing, as well as
by the conditions and duration of storage.
Conclusions. These results validate a simple, low-cost ELISA
and document the optimal conditions of processing and
storage for measuring uromodulin in human urine.
INTRODUCTION
Urinary biomarkers constitute an essential tool for the diagno-
sis, classiﬁcation and prognosis of kidney diseases [1]. Recent
evidence pointed at uromodulin (Tamm–Horsfall protein) as
a potential urinary biomarker relevant for renal function,
chronic kidney disease (CKD) and hypertension [2, 3]. Uromo-
dulin is a 105 kDa glycoprotein with seven N-glycosylation sites
and a high-mannose chain. The protein contains 616 amino
acids including 48 cysteine residues that are all engaged in the
formation of disulphide bonds. Uromodulin contains three epi-
dermal growth factor-like domains and a zona pellucida
domain found in many extracellular proteins, as well as a glyco-
sylphosphatidylinositol-anchoring site [3]. Uromodulin is a
kidney-speciﬁc protein that is exclusively synthesized in the epi-
thelial cells lining the thick ascending limb (TAL) of Henle’s
loop [4]. After proper trafﬁcking and maturation in TAL-lining
cells, uromodulin reaches the apical plasma membrane, to be
cleaved and assembled in the urine as polymers forming a gel-
like structure [5].
Uromodulin is produced at a very high rate in the TAL, and is
by far the most abundant protein in normal urine (excretion:
50–100 mg/day) [6]. Functions attributed to uromodulin include
protection against urinary tract infections; prevention of renal
calculi formation by reducing aggregation of calcium crystals
and inﬂuencing transport processes by regulating the activity of
the sodium-potassium-chloride co-transporter (NKCC2) and/or
the potassium channel ROMK [7, 8]. Interest for uromodulin
was re-ignited when it was discovered that mutations in the
UMOD gene that codes for uromodulin are responsible for a
series of monogenic disorders (familial juvenile hyperuricaemia
nephropathy, medullary cystic kidney disease type 2 or glomeru-
locystic kidney disease) all known as uromodulin-associated
kidney diseases (UAKD) [3]. These disorders are characterized
by severe tubulointerstitial damage, defective urinary concen-
tration, hyperuricaemia and gout, and progressive renal failure
[9]. The mutations often affect cysteine residues, resulting in con-
formational changes and intracellular aggregates of uromodulin.
In turn, the secretion of the protein by the TAL cells is altered, re-
sulting in a strong decrease in the urinary excretion of uromodu-
lin [10–12]. Recently, a number of genome-wide association
studies revealed that variants in the UMOD gene are associated
with markers of renal function and risk of developing hyperten-
sion and CKD in the general population [13–15]. The association
of uromodulin with both monogenic diseases and complex dis-
orders such as CKD and hypertension provides a strong rationale
for evaluating its urinary concentration as a biomarker for renal
function and CKD.
The determination of uromodulin in the urine is hampered
by its capacity to aggregate and the potential instability of such
a complex protein. Documentation of sampling, processing
and storage conditions is thus crucial for accurate uromodulin
quantiﬁcation. Despite the early characterization of antibodies
speciﬁc for human uromodulin [16], the few reports on uro-
modulin dosage yielded conﬂicting results in terms of stability,
storage conditions and processing of human urine [17–20].
Important points such as the potential inﬂuence of urine cen-
trifugation or vortexing, acidiﬁcation or alkalinization, treat-
ment with protease inhibitors, or normalization for urinary
creatinine remain unsolved. Furthermore, earlier immunoas-
says were often based on poorly documented anti-uromodulin
antibodies. Considering the increasing interest for a determi-
nation of uromodulin in the urine, the need for a high-
throughput assay, and the limited and contradictory infor-
mation available, we developed and characterized a enzyme-
linked immunosorbent assay (ELISA) for uromodulin and
used this assay to investigate the stability of uromodulin under
different treatment and storage conditions of human urine.
MATERIALS AND METHODS
Urine sample collection, storage and handling
Analyses were performed on second morning urine samples
collected (mid-stream) in a sterile container from healthy
volunteers aged 18–50 years, and processed within 2 h. This
protocol was approved by the Ethical Committee of the Univer-
sité Catholique de Louvain.
The inﬂuence of human urine sample processing on the
determination of uromodulin (Figure 1) was tested after vor-
texing the sample for 10 s (Vortex-Genie 2; FAUST, Schaff-
hausen, Switzerland); centrifugation for 10 min at 3600 r.p.m.
(Eppendorf Centrifuge 5430, Hamburg, Germany) at room
temperature (i.e. standard protocol for urine processing and
removing cells and debris [21]); treatment with protease
inhibitors (Leupeptin 1 µmol/L; Sigma-Aldrich, St. Gallen,
Switzerland; sodium azide 10 mmol/L); pH adjustment per-
formed by drop titration with 1 N HCl (to pH 2.0) or with 1 N
NaOH (to pH 8.0) using a Hanna HI 2211 pH meter; dilution
using ultrapure deionized water (Destamat Bi 18E; QCS,
Maintal, Germany) versus triton-EDTA (TEA) buffer (0.5%
Triton X-100, 20 mM ethylenediaminetetraacetic acid
(EDTA), pH 7.5). The effect of storage conditions was tested
by comparing baseline levels with 1-week and 5-month
storage at room temperature, +4°C and −20°C; 4- and
8-month storage at −80°C; ﬁve cycles of freezing–thawing
(sample kept at −80°C for 48 h followed by thawing on ice).
Different sample sets were used to evaluate the inﬂuence of the
various processing conditions as described.
Uromodulin ELISA
The in-house ELISA for uromodulin is a colorimetric based
sandwich immunoassay using a sheep anti-human uromodulin
antibody (Meridian Life Science, Memphis, TN, USA;
O
R
IG
IN
A
L
A
R
T
IC
L
E
U r o m o d u l i n i n h u m a n u r i n e
137
K90071C) as the capture antibody. This antibody gives a single
arc when tested by immuno-electrophoresis against fresh urine.
The primary antibody was a monoclonal anti-human uromo-
dulin antibody (Cedarlane Laboratories, Burlington, NC, USA;
CL 1032A) raised in mouse and validated in solid phase radio-
immunoassay. The secondary antibody was a goat anti-mouse
IgG (H + L) horseradish peroxidase conjugated (Bio-Rad, Cres-
sier, Switzerland; 172.1011). The substrate was O-Phenylenedia-
mine dihydrochloride (OPD) (10 mg/tablet) (Sigma-Aldrich).
The OPD substrate solution was freshly prepared by dissolving
a tablet in 25 mL of phosphate-citrate buffer [0.1 M citric acid
monohydrate, 0.2 M Na2HPO4], pH 5.5. A volume of 5 µL 30%
H2O2 was added to 25 mL of substrate solution. Human uro-
modulin (Millipore, Billerica, MA, USA) was used to establish
the standard curve, with freshly prepared serial dilutions from
the standard stock solution (100 µg/mL). Both the standard
curve and a standard sample (uromodulin concentration 25 µg/
mL) were systematically used for quality control (QC).
The determination of urinary uromodulin by ELISA was
carried out as follows: a 96-well microtitre plate (NUNCMaxi-
Sorp™; eBioscience, Vienna, Austria) was coated with 100 µL
of 5 µg/mL capture antibody in coating buffer [500 mM
H3BO3, 500 mM KCl, 345 mM NaOH, pH 9.0]. The plate
covered with adhesive seal was incubated at 4°C overnight
then washed three times with freshly prepared washing buffer
[0.1% Tween 20 in 10 mM phosphate buffer saline (PBS) pH
7.2 (PBS–Tween 0.1%)] using ImmunoWash 1575 Microplate
Washer (Bio-Rad). Unoccupied sites on the plate were blocked
with 100 µL blocking buffer [0.5% bovine serum albumin
(BSA) in 10 mM PBS, pH 7.2] and incubated at 37°C for 1 h
(rotation, 100 r.p.m.). The plate was then washed three times
with washing buffer and placed upside-down on absorbent
paper to remove residual buffer. One hundred microlitres of
PBS–Tween 0.1% was dispensed in all wells. Urine samples
were stabilized at room temperature then diluted 1:50 in ultra-
pure deionized water, as preliminary testing revealed no sig-
niﬁcant difference versus dilution with TEA buffer (data not
shown). A volume of 100 µL per well was distributed into the
coated wells after vortexing. Standards and QC sample were
run in duplicate, whereas each urine sample was tested in
three different dilutions. Deionized water was used as blank.
After 1 h incubation at 37°C, the plate was washed three times
and placed on absorbent paper. One hundred microlitres of
primary antibody diluted in PBS–Tween 0.1% (1 µg/mL) was
dispensed in each well; the plate was incubated at 37°C for 1 h
(rotation, 100 r.p.m.) then washed three times. The secondary
antibody diluted 1:2000 in PBS–Tween 0.1% was added to the
wells for 45 min at 37°C and the plate washed three times.
Colour was developed by adding 100 µL of OPD substrate sol-
ution. The plate was incubated at room temperature in the
dark for 1 min, and the reaction stopped by adding 50 µL of
2 M H2SO4 to each well. Optical density (Inﬁnite M200Pro;
Tecan, Grödig, Austria) was read at 492 nm and urinary uro-
modulin concentration was determined by referring to the
standard curve. Uromodulin levels obtained using the in-
house ELISA were compared with the commercial ELISA from
MD Bioproduct (St. Paul, MN, USA; M036020), following the
protocol given by the manufacturer. This test has been used in
several studies [13, 22]. Urinary creatinine levels (normaliza-
tion) were measured using the Synchron® System Creatinine
Assay (Unicell DxC Synchron®; Beckman Coulter, Brea, CA,
USA), following the manufacturer’s instructions.
Immunoblotting
Kidneys from Umod mice [23] were grounded in liquid ni-
trogen and homogenized as described previously [12]. The
homogenate was centrifuged at 1000 g for 15 min at 4°C and
the resulting supernatant at 100 000 g for 120 min at 4°C. The
pellet was suspended in homogenization buffer before deter-
mination of protein concentration (Pierce BCA protein assay
kit; Thermo Fischer Scientiﬁc, Rockford, IL, USA). Sodium
dodecyl sulphate (SDS)–polyacrylamide gel electrophoresis for
mouse and human samples was performed under reducing
conditions. Samples (20 µg of mouse and human kidney
F IGURE 1 : Processing of urine samples for uromodulin determination. The ﬂow chart describes how urine samples were collected and treated
to validate the protocol of uromodulin determination. Grey boxes represent the standard treatment to measure uromodulin in the urine.
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extract; 2 µL of urine) were loaded after being mixed with
Laemmli sample buffer and heated for 5 min at 95°C (kidney
samples). Proteins were separated on 10% SDS gel and trans-
ferred to nitrocellulose membrane for western blotting. Mem-
branes were blocked with 5% milk blot for 30 min at room
temperature then incubated overnight at 4°C with either sheep
or mouse anti-uromodulin antibodies (1:400 in 0.5% BSA
blocking buffer). Secondary antibodies were goat anti-mouse
horseradish peroxidase (HRP) conjugated (1:10 000) or poly-
clonal rabbit anti-sheep HRP conjugated (1:1000), for 1 h at
room temperature. Antigen-antibody reaction was detected by
using enhanced chemiluminescence (Immun-Star HRP, Bio-
Rad) and light-sensitive ﬁlm (GE Healthcare, Glattbrugg,
Switzerland). The molecular weight was estimated by running
the Precision Plus Protein™ All Blue standard (Bio-Rad).
Deglycosylation and desialylation of uromodulin
Deglycosylation of uromodulin from human urine was
carried out using peptide -N-Glycosidase F (PNGase F)
(PNGase F P0704S; New England Biolabs, Ipswich, MA, USA)
following the manufacturer’s protocol, whereas desialylation
was performed according the protocol described by Parsons
et al. [24]. Brieﬂy, uromodulin was precipitated from pooled
human urine (1.5 L) following the protocol of Tamm and
Horsfall [2], dialysed overnight at 4°C and then lyophilized
(Virtis, Kloten, Switzerland). Dry uromodulin was solubilized
in 2.5 M acetic acid (10 mg/mL), heated for 3 h at 82°C, then
washed three times with 15 mL PBS (pH 7.2) on Centricon
(MWCO 30000) cartridge (Millipore). Of note, 1.5 µL of de-
glycosylated urine and 0.1 µL of desialylated uromodulin
(versus 0.5 µL of untreated urine) were loaded on 10% acryl-
amide gel and analysed as described above.
Immunohistochemistry
Colocalization of uromodulin with NKCC2 was carried out
in cryosections of human and mouse kidney samples as pre-
viously described [10, 12]. Brieﬂy, 5-µm-thick cryosections
were blocked with 1% BSA/0.02% sodium azide-PBS for
30 min at room temperature, incubated for 2 h at room temp-
erature with the sheep (1:400) or mouse (1:200) antibodies
against human uromodulin, followed by washing and incu-
bation with AlexaFluor633-conjugated donkey anti-sheep or
goat anti-mouse (1:200) for 90 min at room temperature. Uro-
modulin-stained sections were then incubated with a polyclo-
nal rabbit anti-NKCC2 antibody (Millipore; AB3562P; 1:100)
for 3 h at room temperature, followed by washing and incu-
bation with Alexaﬂuor488-conjugated goat anti-rabbit anti-
bodies (1:200). Sections were viewed on a Leica SP5 confocal
microscope.
Surface plasmon resonance: Biacore
The interaction between uromodulin and the capture anti-
body was analysed by surface plasmon resonance, using a
Biacore T100 system (GE Healthcare, Uppsala, Sweden).
Chemicals were from Sigma unless otherwise noted. Binding
experiments were performed in PBS buffer pH 7.4 containing
0.2% of Tween 20 at a ﬂow rate of 30 µL/min at 25°C. Ultrapure
and ﬁltered water (‘MilliQ’; Millipore) was used for preparing
all solutions. The carboxymethyl dextran chip (CMD500L;
XanTec bioanalytics, Düsseldorf, Germany) surface (1.2 mm2
area) was cleaned before use by injecting seven times a 50 mM
NaOH solution containing 1 M NaCl for 30 s at a ﬂow rate of
5 µL/min. Surface binding is expressed in terms of changes in
response units (RU) with 1 RU being ∼1 pg/mm2. Sheep poly-
clonal anti-uromodulin antibody (300 nM) in PBS–Tween was
immobilized by amine coupling to the chip surface activated
with aqueous solutions of 0.4 M 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide and 0.1 M N-hydroxysuccinimide for 300 s
at 5 µL/min ﬂow rate. For the determination of kinetic con-
stants, a dilution series of four concentrations (19, 39, 78 and
156 nM) of uromodulin was injected using the T100 in multi-
channel mode. The reference channel used in parallel did not
contain immobilized antibody, in order to detect background
response and unspeciﬁc binding of analyte to the surface.
Between two measurements, the surface was regenerated by in-
jecting twice 10 mM glycine at pH 2 for 30 s, which completely
removed uromodulin from the antibody. For data evaluation,
the measured sensorgrams were referenced twice, ﬁrst by
subtracting the signal from the reference channel, and second
by subtracting the signal obtained from injected pure buffer
solution. Kinetic curves were evaluated using Biacore T100
Evaluation Software (v. 2.0.2). A global ﬁt was performed using
the entire concentration series. Rate constants for association
and dissociation were calculated by taking a 1:1 binding model
as a basis.
Data analysis
Data were analysed using Statistical Package for Social
Sciences (SPSS) version 19 (IBM Corp., Armonk, NY, USA).
The Pearson correlation coefﬁcient was used for correlation
analysis, whereas analysis of variance (ANOVA) and paired
t-test were used for comparisons between the groups. A
Bland–Altman plot was used to evaluate agreement between
uromodulin levels measured with the in-house ELISA and
commercial kit. The level of signiﬁcance was set to P < 0.05.
RESULTS
Characterization of the antibodies against human
uromodulin
The antibodies used for the in-house ELISAwere character-
ized by immunoblotting and immunostaining (Figure 2).
Immunoblot analysis of human urine and kidney samples in
parallel with mouse kidney samples using the sheep polyclonal
antibodies detected the uromodulin band at ∼100 kDa in
all samples except the Umod knock-out (KO) kidney sample.
The uromodulin band was also detected in human urine and
kidney samples using the mouse monoclonal antibody
(Figure 2A, top panel). Both the polyclonal and monoclonal
antibodies also appropriately identiﬁed the deglycosylated and
desialylated forms of uromodulin (Figure 2A, lower panels).
Staining of human and mouse kidney tissue samples with
the mouse monoclonal or the sheep polyclonal antibodies
detected uromodulin in the TAL, where it colocalized with
NKCC2 at the apical surface area (Figure 2B). Surface
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F IGURE 2 : Characterization of anti-human uromodulin antibodies. (A) Western blot analysis (10% acrylamide gel) of human urine (2 µL),
human kidney tissue (20 µg) and Umod knock-out (KO) and wild-type (WT) mouse kidney tissue (20 µg) using the sheep polyclonal or the
mouse monoclonal antibodies against human uromodulin. A single band at ∼100 kDa is detected with both antibodies, and absent in the Umod
KO mouse kidney (top panel). The changes in molecular mass resulting from deglycosylation (lower left panel) and desialylation (lower right
panel) of uromodulin are evidenced by using both the polyclonal and monoclonal anti-uromodulin antibodies. Of note, 1.5 µL of deglycosylated
urine and 0.1 µL of desialylated uromodulin (versus 0.5 µL of untreated urine) were loaded the gel. (B) Immunostaining of human cortical
O
R
IG
IN
A
L
A
R
T
IC
L
E
S. Youhanna et al.
140
plasmon resonance [25] was further used to characterize
the uromodulin—antibody interaction (Figure 2C). As the
isoelectric point of uromodulin (pI = 3.2) is too low for its
immobilization to a carboxymethyl dextran surface, the
capture sheep anti-uromodulin antibodies were immobilized
at the surface of a sensor chip, and a dilution series of uromo-
dulin was injected. For the interaction of immobilized sheep
anti-uromodulin antibody with uromodulin, rate constants for
association (kon) and dissociation (koff ) of 4 × 10
4 M−1 s−1 and
4 × 10–4 s−1, respectively, were determined, giving a dis-
sociation constant KD (=koff/kon) of 10 nM. We also measured
a strong binding response for the interaction of mouse anti-
human uromodulin antibody to the sheep anti-uromodulin
antibody—uromodulin complex. This situation is comparable
with the conditions in ELISA (see below). Regeneration of
the surface with 10 mM glycine at pH 2.0 removed both the
antibody and uromodulin.
Characteristics of the ELISA for uromodulin
When tested against puriﬁed human uromodulin, the in-
house ELISA for human uromodulin showed a sensitivity
(minimum amount of analyte which can be accurately de-
tected) of 2.8 ng/mL and a linearity (correlation between
concentration and optical density) of 1.0 (Figure 3A). The
inter- and intra-assay variabilities were determined at 3.28 and
5.46%, respectively. The assay had a detection range between
3.9 and 500 ng/mL. When compared with other assays, the in-
house ELISA showed a wider range of measurement and
lower intra- and inter-assay variability than commercially
available routine kits (Table 1). There was a robust correlation
(r = 0.905, P < 0.001) when comparing the in-house ELISAwith
the MD Bioproduct kit. The Bland–Altman plot showed that
the mean difference between both methods was −1.47 µg/mL
(95% CI, −3.21 to 0.27 µg/mL) (Figure 3B).
Inﬂuence of processing of urine samples
Since uromodulin has a tendency to aggregate, we ﬁrst inves-
tigated the potential inﬂuence of vortexing and centrifugation
on the determination of uromodulin levels in human urine
(Table 2). Comparison of fresh samples assayed before and
after vortexing revealed a >50% increase in uromodulin levels
(unindexed uromodulin: 5.02 ± 0.66 versus 11.03 ± 1.67 µg/mL,
respectively, P = 0.001; indexed uromodulin: 10.84 ± 0.54 versus
15.90 ± 1.45 mg/g creatinine, respectively, P = 0.001, n = 37).
Treating the urine samples with a usual centrifugation protocol
(10 min, 3600 r.p.m.) also showed a signiﬁcant decrease in un-
indexed (6.40 ± 0.63 versus 13.27 ± 1.18 µg/mL, respectively,
P < 0.001) and indexed (9.97 ± 1.43 versus 15.66 ± 1.34 mg/g
creatinine, respectively, P < 0.001, n = 53) uromodulin levels.
Immunoblotting analyses (Figure 4) revealed that centrifugation
induced the precipitation of uromodulin in the pellet of cell
debris. In comparison with the uromodulin band detected in
fresh, non-centrifuged urine samples, the signal was strongly at-
tenuated in the centrifuged urine sample while becoming
apparent in the resulting pellet.
Alkalinization of fresh urine sample to pH 8.0 did not
inﬂuence the determination of urinary uromodulin, when
compared with untreated (mean pH 5.68 ± 0.19) samples (un-
indexed uromodulin: 19.25 ± 4.14 versus 20.60 ± 5.24 µg/mL,
respectively, P = 0.179; indexed uromodulin: 17.56 ± 2.28
versus 18.34 ± 2.67 mg/g creatinine, respectively, P = 0.260,
n = 14). Likewise, acidiﬁcation of urine samples to pH 2.0 did
not result in a signiﬁcant difference between values from un-
treated (mean pH 6.15 ± 0.59) samples (unindexed uromodu-
lin: 10.01 ± 2.25 versus 9.73 ± 2.07 μg/mL, respectively,
P = 0.621; indexed uromodulin: 18.86 ± 8.26 versus
19.10 ± 8.55 mg/g creatinine, respectively, P = 0.782, n = 8).
Inﬂuence of storage conditions
In order to cast light on the inﬂuence of storage conditions
on the stability of uromodulin, we compared values obtained
in samples analysed at baseline and after 1-week or 5-month
storage at room temperature, +4°C and −20°C. When com-
pared with baseline, storage at either room temperature or 4°C
or even −20°C was associated with decreased levels of both
unindexed and indexed uromodulin (Table 3). Addition of
protease inhibitors at the time of collection had some effect on
the degradation of the samples conserved at −20°C, but not on
those kept at +4°C. In any case, the addition of protease
inhibitors was insufﬁcient to prevent a signiﬁcant decrease in
the uromodulin levels when compared with baseline values. In
contrast, 4-month storage at −80°C was not associated with
signiﬁcant changes in uromodulin levels in untreated
samples. Further analyses revealed a slight but signiﬁcant de-
crease after 8-month storage at −80°C (baseline uromodulin:
23.73 ± 1.57 µg/mL versus 8 months: 20.13 ± 1.17 µg/mL,
P = 0.023, n = 142). Freezing–thawing cycles (from −80 to
0°C) showed no signiﬁcant changes in the levels of urinary
uromodulin when compared with baseline (Table 4).
DISCUSSION
Increasing evidence suggests that the level of uromodulin in
urine could represent a useful biomarker for kidney function
[3, 26]. In this study, we validated an efﬁcient and cost-
effective immunoassay and characterized the conditions of
kidney sections (top row) using polyclonal sheep antibodies against human uromodulin (red), evidencing the apical staining in TAL proﬁles that
are also positive for NKCC2 (green). A similar co-distribution between uromodulin (red) and NKCC2 (green) is observed in mouse kidney,
using the polyclonal (middle row) or monoclonal (bottom row) anti-uromodulin antibodies. Scale bar: 10 µm, inset: 2× zoom. (C) Sensorgrams
for the interaction of puriﬁed human uromodulin (19–156 nM) with the immobilized sheep anti-uromodulin antibody by surface plasmon res-
onance technique using the Biacore system. Uromodulin was injected at 0 for 300 s. Red lines are the result of a global ﬁt. The constant of dis-
sociation (KD) was determined after evaluating the association (kon) and dissociation (koff ) rate constants simultaneously using 1:1 kinetic
binding model.
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sampling and storage necessary to provide a faithful dosage of
uromodulin in human urine. The urinary uromodulin levels
were signiﬁcantly affected by centrifugation and vortexing, as
well as by the conditions and duration of storage.
To develop the in-house ELISA, we used commercially
available anti-uromodulin antibodies and validated their
speciﬁcity in human and mouse kidney and urine samples.
Both antibodies evidenced the ∼100 kDa band corresponding
to uromodulin on immunoblot, either in native or deglycosy-
lated/desialylated state. They also showed the typical distri-
bution along with NKCC2 in the apical membrane of the
TAL. We used plasmon surface resonance to determine the
binding constant for interaction of the immobilized sheep
anti-uromodulin antibody to uromodulin to 10 nM which is
in the expected range for an antibody-protein interaction. The
immunoassay standard curve showed linearity over a broad
F IGURE 3 : Characterization of the in-house ELISA for uromodulin. (A) Standard curve of absorbance for a dilution series (500, 250, 125, 68,
34, 17, 8.5 and 3.9 ng/mL) of puriﬁed human uromodulin. (B) Bland–Altman plot: difference between uromodulin levels measured with in-
house ELISA and the commercial kit plotted against mean uromodulin levels measured with both methods (n = 28). Horizontal lines represent
the mean difference for the whole group (−1.47 µg/mL) and the 95% limits of agreement (−10.40 – 7.45 µg/mL).
Table 1. Comparison of the characteristics of the in-house ELISA for uromodulin and the
commercially available ELISA kits
Kit Detection range (standard curve)
(ng/mL)
Inter-assay variability
(%)
Intra-assay variability
(%)
In-house 3.9–500 3.28 5.46
MD Bioproduct (Cat. M036020) 2.34–150 11.63 8.36
BioVendor (Cat. RD191163200R) 0.5–32 6.4 2
USCN Life Science, Inc.
(Cat. E96918 Hu)
3.13–200 <12 <10
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range of values, allowing the detection of uromodulin with
high sensitivity and very low inter- and intra-assay variability.
It must be noted that, in contrast with previous results
based on immunoblotting [20], dilution of the samples with
deionized water yielded similar results than with TEA buffer.
All these features, combined with an excellent correlation with
the most used commercial ELISA, substantiate the interest of
our immunoassay with the advantage of low cost, wide range
of detection and low variability.
Our analyses revealed a striking effect of vortexing and cen-
trifugation on the determination of uromodulin in the urine.
These two procedures yielded variations reaching 50% of the
levels obtained on control, unprocessed samples (Table 2). These
ﬁndings are clinically relevant, because low levels of urinary uro-
modulin have been suggested to be of diagnostic value in UAKD
[3, 9–11]. The effect of vortexing conﬁrms the importance of the
aggregation of uromodulin molecules in the normal urine. Uro-
modulin is also known to cofractionate with exosomes [27], the
recovery of which is increased by vortexing [28]. Uto et al. [18]
previously suggested that uromodulin may be trapped in cell
debris or aggregated with crystals after centrifugation protocols
that are usual to remove contamination due to lysis or suspended
cells [29]. Our data conﬁrm these ﬁndings and show that cen-
trifugation of urine may decrease the level of uromodulin by
∼30%. Thawed urine samples should thus be vortexed but not
centrifuged before assaying uromodulin.
The stability of uromodulin during different storage proto-
cols is critical for analysing large, multicentric cohorts.
Previous studies based on small sample size yielded inconsist-
ent conclusions about the inﬂuence of storage duration and
temperature [17–20]. Furthermore, these studies did not take
into account normalization for urinary creatinine, which is
usual for kidney biomarkers [29, 30]. Our results, obtained on
a large number of samples, reveal that short (1 week) and
longer (5 months) storage at room temperature, 4 or −20°C
causes a signiﬁcant decrease in indexed urinary uromodulin
levels, largely due to decreased uromodulin. In contrast, a 4-
month storage at −80°C is associated with marginal, non-sig-
niﬁcant decrease in the unindexed and indexed values. Of
note, the decrease in unindexed uromodulin levels becomes
signiﬁcant after an 8-month storage at −80°C. The fact that
storage of untreated urine samples at room temperature, 4°C
or −20°C signiﬁcantly decreases the level of uromodulin sub-
stantiates the observations of Kobayashi and Fukuoka [20].
This effect is only partially attenuated with protease inhibitors,
which show some effect for samples kept at −20°C—but insuf-
ﬁcient to prevent a signiﬁcant degradation. Taken together,
these data conﬁrm the fact that urine samples should be stored
at −80°C and analysed within 3 months to give the most
reliable measurements. Of note, up to ﬁve freezing–thawing
cycles on ice did not affect the stability of uromodulin stored
at −80°C.
Previous studies also reported inconsistent results in terms of
treatments (detergents or TEA buffer, alkalinization) supposed
to solubilize aggregates of uromodulin in urine [17–20, 31].
Some of these treatments may interfere with the binding of
uromodulin to the ELISA capture antibody [18]. We veriﬁed
here that dilution with deionized water gave similar results than
with TEA, and that urine alkalinization (or acidiﬁcation) had
no effect on the determination of uromodulin. These data
support the conclusion that dilution of the sample with water
before the assay, combined with vortexing, is an efﬁcient way of
disaggregation [31].
In summary, these data indicate that reliable uromodulin
measurements can be obtained from untreated urine samples,
provided they are immediately stored at −80°C and assayed
within 3 months, with vortexing and dilution with water to
prevent aggregation. This methodology will be useful for high-
throughput analyses of uromodulin and its validation as a
biomarker for renal function and risk of CKD.
Table 2. The effect of sample processing (vortex and centrifugation) on the concentration of
uromodulin in the urine
Unindexed uromodulin
(µg/mL)
P-value Indexed uromodulin
(mg/g creatinine)
P-value n
Vortex 11.03 ± 1.67 0.001 15.90 ± 1.45 0.001 37
No vortex 5.02 ± 0.66 10.84 ± 0.54
Centrifugation 6.40 ± 0.63 <0.001 9.97 ± 1.43 <0.001 53
No centrifugation 13.27 ± 1.18 15.66 ± 1.34
Urine samples were vortexed for 10 s. Centrifugation was performed for 10 min at 3600 r.p.m. at room temperature. Two different sets of
samples were used to test the inﬂuence of vortexing (n = 37) and centrifugation (n = 53).
F IGURE 4 . Effect of urine centrifugation on the detection of uro-
modulin. Western blot analysis (10% acrylamide gel) of two human
urine samples (S1 and S2) using the polyclonal sheep anti-uromodu-
lin antibody: the signal obtained in baseline urine is lost when analys-
ing the supernatant following centrifugation, whereas a clear signal
appears in the pellet. Similar volumes (2 µL) of untreated urine,
supernatant and resuspended pellet were loaded.
O
R
IG
IN
A
L
A
R
T
IC
L
E
U r o m o d u l i n i n h u m a n u r i n e
143
ACKNOWLEDGEMENTS
These studies were supported in part by an Action de
Recherche Concertée (ARC, Communauté Française de
Belgique); the FNRS and FRSM; the Inter-University Attrac-
tion Pole (IUAP, Belgium Federal Government); the NCCR
Kidney. CH program (Swiss National Science Foundation); the
European Community’s Seventh Framework Programme
(FP7/2007-2013) under grant agreement no 246539 (Marie
Curie) and grant no 305608 (EURenOmics) and the Gebert
Rüf Stiftung (Project GRS-038/12). The expert assistance of
N. Amraoui, H. Debaix, S. Druart, Z. Guo and S. Terryn is
appreciated. We thank Dr L. Rampoldi for providing the
kidney extract obtained from the Umod KO mouse developed
by Professor X.-R. Wu [21], and Dr S. Schauer for helpful
discussions about the Biacore experiments.
Table 3. The effect of storage conditions (duration, temperature and protease inhibitors) on the
concentration of uromodulin in the urine
Unindexed uromodulin (µg/mL) P-value Indexed uromodulin
(mg/g creatinine)
P-value n
1-week storage
Baseline 12.39 ± 2.41 0.078a 22.70 ± 3.35 0.014a 13
RT 6.14 ± 1.34* 13.00 ± 2.34*
+4°C 7.22 ± 1.60* 11.49 ± 1.50*
−20°C 9.98 ± 1.96* 18.69 ± 3.18*
4-month storage
Baseline 36.37 ± 2.62 0.354 24.05 ± 1.26 0.412 61
−80°C 35.47 ± 2.32 23.30 ± 1.25
5-month storage
Baseline 28.50 ± 6.76 26.48 ± 3.45 10
+4°C 10.17 ± 3.96* 0.068a 10.27 ± 2.35* 0.001a
−20°C 16.52 ± 5.08* 15.78 ± 2.73*
+4°C and PI 11.04 ± 4.69* 0.111a 10.80 ± 2.32* 0.003a
−20°C and PI 20.23 ± 5.27*,** 18.71 ± 2.69*,**
PI, treatment with protease inhibitors (Leupeptin and sodium azide). Three different sets of urine samples were used to assess inﬂuence of
storage after 1 week (n = 13), 4 months (n = 61) and 5 months (n = 10) versus baseline levels.
aANOVA.
*P < 0.05 storage condition versus baseline.
**P < 0.05 no versus protease inhibitors, paired t tests.
Table 4. The effect of freezing–thawing cycles on the concentration of uromodulin in the urine
Unindexed uromodulin (µg/mL) P-value Indexed uromodulin (mg/g creatinine) P-value n
Freezing–thawing cycles (−80 to 0°C)
Baseline 22.96 ± 4.75 0.616a 18.14 ± 2.82 0.351a 8
1 22.01 ± 3.81 20.19 ± 3.51
2 24.74 ± 4.05 23.67 ± 3.07
3 16.74 ± 2.68 18.17 ± 2.58
4 16.96 ± 3.36 16.20 ± 1.98
5 19.42 ± 4.56 15.91 ± 2.42
aANOVA.
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